StockUS listing USSHJBFPINKHealthcareValue Trap

Shanghai Junshi Biosciences Co. Ltd(SHJBF) Stock Analysis | Healthcare

USD --+0.00%
Reward40Moderate
Risk55Medium-High
75%Data
Thin -38% profit margin · Revenue growing 31% YoY
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 4.12Bn
Reward Ratingⓘ40 Moderate reward assessment · 75% data coverage
Bottom 10% of stocksView factors
Risk Ratingⓘ55 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on SHJBF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Shanghai Junshi Biosciences Co. Ltd?

, a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China.

AI Brief Pro

The brief on Shanghai Junshi Biosciences Co. Ltd

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Shanghai Junshi Biosciences Co. Ltd?

, a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 4.12B.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (40)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.794
Insider Activity
12M windowNo data
No insider activity data available for this ticker.